Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Ginkgo Bioworks Holdings

Stocks Flashing Renewed Technical Strength: Ginkgo Bioworks Holdings

A Relative Strength Rating upgrade for Ginkgo Bioworks Holdings shows improving technical performance.

Investors Business Daily

Ginkgo Bioworks Holdings Meets 80-Plus Relative Strength Rating Benchmark

Ginkgo Bioworks Holdings sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Upgrades

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking Into Ginkgo Bioworks Holdings's Recent Short Interest

Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has risen 9.65% since its last report. The company recently reported that it has 81.30 million shares sold short, which is 10.34% of all regular shares that are available for trading.

Benzinga

8 Materials Stocks Moving In Tuesday's Pre-Market Session

Gainers Ginkgo Bioworks Holdings (NYSE:DNA) shares rose 9.9% to $4.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.8 billion. The company's, Q4 earnings came out yesterday.

Benzinga

Should You Add Ginkgo Bioworks Holdings to Your Biotech Portfolio?

Ginkgo Bioworks (DNA) went public last September through an SPAC deal with Soaring Eagle Acquisition Corporation, a blank-check company led by former MGM CEO Harry Sloan. However, the stock has nosedived in price since its market debut. In addition, given an ongoing investigation into the company and its weak financials,…

Organisations

Bank of New York Mellon

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.